USSN: 10/593,413 - 3 -

Attorney Docket No: 0220.00002

CLAIMS:

1. (Currently amended) An immunogenic hybrid polypeptide, in which a the C-terminus of a peptide is fused to the *N*-terminus of a helper T cell epitope, said peptide comprising one or more copies of an amino acid sequence selected from the group consisting of SEQ ID Nos. 1, 2 and 3 is fused to an N-terminus of a helper T cell epitope.

- 2. (Currently amended) The polypeptide according to claim 1, wherein the peptide is prepared by linking two to eight copies of the amino acid sequence selected from the group consisting of SEQ ID Nos. 1, 2 and 3.
- 3. (Currently amended) The polypeptide according to claim 2, wherein the peptide is prepared by linking four copies of the amino acid sequence selected from the group consisting of SEQ ID Nos. 1, 2 and 3.
- 4. (Original) The polypeptide according to claim 3, wherein the peptide is prepared by linking four copies of the amino acid sequence of SEQ ID No. 1.
- 5. (Original) The polypeptide according to claim 4, wherein the peptide is a polypeptide having an amino acid sequence of SEQ ID No. 5.
- 6. (Original) The polypeptide according to claim 1, wherein the helper T cell epitope is selected from the group consisting of hepatitis B surface antigen helper T cell epitopes, *Chlamydia trachomitis* major outer membrane protein helper T cell epitopes, *Plasmodium falciparum circumsporozoite* helper T cell epitopes, *Escherichia coli* TraT helper T cell epitopes, Tetanus toxoid helper T cell epitopes, diphtheria toxoid helper T cell epitopes, *Schistosoma mansoni* triose phosphate

USSN: 10/593,413 - 4 -

Attorney Docket No: 0220.00002

isomerase helper T cell epitopes, measles virus F protein helper T cell epitopes, and

rabies virus helper T cell epitopes.

7. (Original) The polypeptide according to claim 6, wherein the T cell epitope is a

helper T cell epitope of the hepatitis B surface antigen.

8. (Original) The polypeptide according to claim 7, wherein the T cell epitope is a

preS2 helper T cell epitope of the hepatitis B surface antigen.

9. (Original) The polypeptide according to claim 8, wherein the T cell epitope has

an amino acid sequence of SEQ ID No. 7.

10. (Original) The polypeptide according to claim 1, which has an amino acid

sequence of SEQ ID No. 9.

11. (Original) A vaccine for preventing or treating obesity, comprising the

polypeptide of any one of claims 1 to 10.

12. (Original) A recombinant vector comprising a gene encoding the polypeptide

of any one of claims 1 to 10.

13. (Original) The recombinant vector according to claim 12, which is pB1₄T

(KCCM-10562).

14. (Original) A host cell transformed with the recombinant vector of claim 12.

USSN: 10/593,413 - 5 -

Attorney Docket No: 0220.00002

15. (Original) A method of preparing the polypeptide of claim 1 by culturing the host transformed with the recombinant vector cell of claim 12.